chondral bone formation. 16, 25 Direct delivery of the BMP-2 gene via a first-generation adenoviral vector has also been shown to promote osteoinduction strongly in the thigh musculature of athymic nude rats. 4 Several research groups have also demonstrated the ability of ex vivo and direct BMP-2 gene therapy to induce spinal fusion in rodents and rabbits. 2, 3, 30 In addition, direct BMP-2 and BMP-9 adenoviral gene therapy has been previously shown to be effective in repairing bony defects in the craniofacial region. 1 It may be possible, however, that other bone morphogens or a cocktail of proteins may have significantly more osteoinductive activity than BMP-2. For example, Boden et al., 6 have recently reported that LIM mineralizing protein-1 ex vivo gene therapy can successfully induce spinal fusion in rodents, apparently by upregulating the expression of a variety of bone morphogens.
Although BMP-9 has been shown to exert only mild in vivo osteoinductive effects when applied to a biological carrier, BMP-9 gene therapy may be more potent and efficacious. 9 A first-generation BMP-9 adenoviral vector has been shown to induce massive amounts of ectopic bone formation in the thigh musculature of immunocompetent and athymic nude rats, and it seems to promote endochondral bone formation at an extremely fast rate (Fig. 1) . Because BMP-9 gene therapy may prove to be a more effective technique than BMP-2 gene therapy for promoting ectopic bone formation, the present study was undertaken to determine whether a BMP-9 adenoviral vector injected percutaneously can induce spinal arthrodesis in the athymic nude rodent.
Materials and Methods
The host immune response has been shown to significantly limit transgene expression of first-generation adenoviral vectors. For this reason, eight 16-week-old male athymic nude rats were used for this study. 13 
Adenoviral Constructs
First-generation, Type 5 adenoviral vectors that were made replication defective through complete deletion of the E1a and E1b regions and through partial deletion of the E3 region of the viral genome were used in this study. The Ad-BMP-9 (Genetics Institute, Andover, MA) was constructed with the BMP-9 gene under the control of a cytomegalovirus promoter. The BMP-9 complementary DNA was a chimera of the murine BMP-9 proregion (first two thirds of N 2 terminus) and the human mature region. A second adenoviral vector containing the ␤-galactosidase (␤-gal) gene under the control of the cytomegalovirus promoter (Ad-␤-gal) was used as a control. The viruses were propagated on 293 cells and purified by two rounds of cesium chloride centrifugation. The purified virus was dialyzed in PBS. These viruses were stored until use at Ϫ80˚C in PBS, 10% glycerol at a concentration of 10 8 pfu/l.
Injection Procedure
The eight rats were anesthetized with a mixture of ketamine and xylazine, and the lumbosacral area was prepared in a sterile fashion. With fluoroscopic guidance, each animal underwent paraspinal, percutaneous injection at the lumbosacral junction with 7.5 l (7.5 ϫ 10 8 pfu) of virus with Ad-BMP-9 on the right and Ad-␤-gal on the left. To ensure correct placement of the vector, a 19-gauge guide needle was inserted in the junction of the spinous process and lamina on each side. A Hamilton microsyringe was inserted through this needle, and 7.5 l of the viral solution (7.5 ϫ 10 8 pfu) was injected.
Imaging Analysis
The animals were sedated, and CT scans of the lumbosacral junction were obtained at Weeks 4, 6, 12, and 16 postinjection. Axial CT images with a 1-mm collimation and 1-mm table increment were obtained using the standard algorithm with 130 kV, 100 mA, a 2-second scan time, and a 40-mm image size. The three-dimensional reconstruction was performed using a Voxel Q workstation.
Histological Analysis
At 16 weeks postinjection, the rats were anesthetized and underwent transcardial perfusion with 100 ml of PBS followed by 350 ml of a 4% paraformaldehyde solution. The lumbosacral spines were harvested and treated with a decalcifying solution composed of 10% HCl and 0.1% ethylenediamine tetraacetic acid. The specimens were dehydrated through a series of graded ethanols, xylol, and finally, xylene, after which the spines were infiltrated and embedded in paraffin. Using a microtome, the tissue was sectioned into 16-m slices and mounted on treated slides. After drying overnight, the slides were stained with Alcian blue (pH 2.5), nuclear fast red, and hematoxylin and eosin, after which all slides were coverslipped.
Results
None of the Ad-BMP-9-injected animals displayed evidence of systemic or local toxicity related to the gene therapy treatment. In addition, the animals remained neurologically intact throughout the postoperative period and no evidence of meningeal irritation or nerve root compression was demonstrated.
Computerized Tomography Studies
Computerized tomography scans demonstrated clear evidence of osteogenesis at the paraspinal Ad-BMP-9 injection sites (Fig. 2 upper left) . The newly formed bone appeared to be in direct contact with the host spinous processes and laminae, without evidence of any intervening soft tissue. The volume of induced bone was significant, extending posteriorly to the top of the spinous process and laterally to the facet joints. There was no evidence of spinal canal compromise by the development of bony overgrowth deep to the ligamentum flavium. The volume of new bone formation was subsequently visualized in three-dimensional CT reconstructions (Fig. 2 upper right and lower left and right).
Histological Findings
Histological examination of the injection sites 4 months after treatment demonstrated a well-developed fusion mass consisting of lamellar bone containing normal bone marrow elements (Fig. 3) . Because only small amounts of residual cartilaginous tissue were found within the fusion mass, we inferred that the tissue had almost completely progressed through the endochondral bone formation pathway. The lamellar bone contained mature osteocytes, and normal-appearing osteoblasts and osteoclasts lined the marrow cavities. The marrow spaces contained histologically normal bone marrow cells, including lymphocytes and adipocytes. The induced bone was clearly demarcated from the surrounding paraspinal musculature, and there appeared to be no normal or atrophied muscle fibers traversing the fusion mass. In addition, the bone was well integrated with the adjacent host bone, although some areas were found to demonstrate persistent host periosteum, which appeared to have a cartilaginous phe-notype. However, there was clear bone union between the adjacent spinous processes, indicating that a successful percutaneous spinal fusion had been achieved. Despite the massive bone deposition induced by Ad-BMP-9, there was no histological evidence of spinal canal compromise or nerve root compression, suggesting that this approach may be acceptable for development in the clinical setting. In addition, histological analysis of the liver demonstrated no evidence of inflammation, cell death, or cellular proliferation.
Discussion
In the present study, we have demonstrated that BMP-9 gene therapy has the potential to become a useful, minimally invasive technique to induce spinal arthrodesis. In a previous study, 4 our group clearly demonstrated the ability of Ad-BMP-2 to induce osteogenesis in the paraspinal region, although the volume of bone formed was significantly less than that in the current study. This is consistent with previous rodent BMP-2 and BMP-9 gene therapy studies performed in the thigh musculature. 2, 19 Although a time course study of the histological findings obtained at the spinal BMP-9 injection site was not performed, the results of a previous study clearly demonstrated the mechanisms by which Ad-BMP-9 induces bone formation in ectopic locations (Fig. 1) . 19 The Ad-BMP-9 transduces the muscle fibers, which express and secrete BMP-9. The extracellular BMP-9 subsequently stimulates pluripotent stem cells to migrate to the injection site and proliferate between the muscle fibers. These cells then differentiate into small chondrocytes that produce a loose cartilaginous matrix, and the matrix calcifies to form woven bone, which finally remodels into normal lamellar bone. 19 The only other study concerning the osteoinductive activity of BMP-9 was a brief report by Celeste, et al., 9 who demonstrated that BMP-9 on a biological carrier could stimulate ectopic bone formation, but only when applied at very high concentrations. Bone morphogenic protein-9 gene therapy studies have been more promising, demonstrating that muscle cells that express BMP-9 can strongly induce bone formation, even compared with BMP-2, the prototypical bone morphogen. 19 However, the discrepancy between the osteoconductive activity of BMP-9 when delivered via a carrier compared with gene therapy remains unclear.
The use of BMP-9 gene therapy has the potential for numerous local and systemic side effects. In all previous BMP studies, however, the expression of BMPs in the paraspinal region by using gene therapy techniques does not lead to neural compression. As vector doses are increased, the migration and proliferation of mesenchymal stem cells into the spinal canal or neural foramen has the potential to become problematic. Precise localization by using stereotactic techniques of the appropriate vector, as well as detailed dosing studies in large animals, will be essential to minimize the risk of neurological complications. The recent development of inducible expression systems may make it possible to control BMP production in vivo. 15, 17, 18, 27 We are currently constructing a novel adenoviral vector containing a tetracycline-responsive promoter to regulate expression of a BMP gene. 17, 18 Cells transduced by this vector will express the bone morphogen when the experimental animal is treated with tetracycline or one of its derivatives, but gene expression should drop to nonphysiological levels in the absence of tetracycline. The development of inducible promoters is currently in its early stages, although we anticipate that with increasing interest in gene therapy, novel inducible systems with tighter control of gene expression should be available in the near future.
Song, et al., 38 have demonstrated that BMP-9 receptors appear to be similar in size to the typical Type I and Type II receptors used by transforming growth factor-␤ family members. Therefore, BMP-9 most likely phosphorylates a Smad second messenger system intracellularly to regulate gene expression in the nucleus. 11, 12 Because BMP-9 receptors are present in the liver and appear to be involved in hepatocyte proliferation, it is still unknown whether there could be any hepatic toxicity related to the local delivery of Ad-BMP-9 to paraspinal musculature in humans. However, none of the treated rodents demonstrated evidence of hepatic or local toxicity related to the paraspinal Ad-BMP-9 injections.
The application of BMPs and BMP gene therapy may not be limited to spinal arthrodesis. The morphogens may also play a crucial role in the treatment of spinal fractures and osteoporosis. Direct injection of the BMP vector into the fractured or osteopenic vertebral body may stimulate the recruitment and proliferation of stem cells into the marrow cavity, and have a direct proliferative effect on local osteoblasts, leading to focal bone deposition at the injection site. However, because the bone marrow cavity is essentially a venous channel with a relatively high blood flow rate, the vector may be washed out into the peripheral circulation before adequate cellular transfection has occurred. Hence, larger volumes of virus may need to be applied to these regions. This could lead to increased systemic toxicity and may, therefore, need to be modified by injecting the virus in embolic agents.
To further target expression of the bone morphogen to the treatment site, transductional or transcriptional targeting may also prove to be useful. 27 Transductional targeting techniques involve the surface modification of viral or nonviral vectors with antibodies so that they have a propensity to bind to specific cell types. This approach may increase not only cell specificity but also the transfection rate. In transcriptional targeting, on the other hand, tissue-specific promoters are used to drive the transgene of interest only in cell types that normally express the promoter's gene. For example, the myosin promoter could be used to target transgene expression to muscle cells, whereas the osteocalcin promoter would limit expression to osteoblasts and osteocytes. 23, 24, 27 Using these promoters, gene expression would be limited to the injection site, because leakage of the vector into the peripheral circulation would be cleared by hepatocytes, which would not express the transgene. The combination of a cell specific gene expression with an inducible system is even more compelling, especially for the treatment of diffuse, chronic bone disorders such as osteoporosis. As more bone morphogenic proteins are identified, their specific in vivo activity will need to be assessed in detail to maximize their usefulness in the clinical setting. For example, some bone morphogens may induce a strong chemotactic response, whereas others may have a stronger effect on osteoblast proliferation and osteoid deposition. Eventually, a cocktail of vectors expressing different homodimeric and/or heterodimeric BMPs in a specific temporal fashion will maximize the volume of newly formed bone, minimize the time course for osteoinduction, and improve the final biomechanical properties of the genetically engineered bone. 22 
